REPORT ON THE RESEARCH UNIT:
Therapeutic Optimization in Neuropsychopharmacology

UNDER THE SUPERVISION OF THE FOLLOWING INSTITUTIONS AND RESEARCH BODIES:
Université Paris Descartes
Université Paris Diderot
Institut National de la Santé et de la Recherche Médicale - INSERM

EVALUATION CAMPAIGN 2017-2018
GROUP D

In the name of Hcéres[1]:

Michel Cosnard, President

In the name of the expert committee[2]:

Radhouane Dallel, Chairman of the committee

This report is the sole result of the unit's evaluation by the expert committee, the composition of which is specified below. The assessments contained herein are the expression of an independent and collegial reviewing by the committee.

UNIT PRESENTATION

Unit name:	Therapeutic Optimization in Neuropsychopharmacology
Unit acronym:	
Requested label:	UMR_S
Application type:	Renewal
Current number:	1144
Head of the unit (2017-2018):	Mr Jean-Louis LAPLANCHE
Project leader (2019-2023):	Mr Jean-Louis LAPLANCHE
Number of teams:	3

COMMITTEE MEMBERS

Chair:	Mr Radhouane DALLEL, Université Clermont Auvergne
Experts:	Ms Catherine BELZUNG, Université de Tours
	Mr Olivier FARDEL, Université de Rennes (representative of CNU)
	Mr Jean-François GHERSI-EGEA, Centre de Recherche en Neurosciences Lyon
	Ms Catherine LE MOINE, INCIA, Université de Bordeaux (representative of CoNRS)
	Mr Pierre MARQUET, Université de Limoges (representative of INSERM CSS)
	Ms Caroline VOUILLAC-MENDOZA, Université Bordeaux (supporting personnel)

HCERES scientific officer:

Ms Céline SOUCHAY

Representatives of supervising institutions and bodies:

Mrs Jean-Louis BEAUDEUX, Université Paris Descartes

Ms Christine GUILLARD, Inserm

Ms Catherine LABBE-JULLIE, Université Paris Descartes

Mr Matthieu RESCHE-RIGON, Université Paris Diderot

Mr Michel VIDAL, Faculté de Pharmacie de Paris

INTRODUCTION

HISTORY AND GEOGRAPHICAL LOCATION OF THE UNIT

The unit is located within the Faculty of Pharmacy-Paris Descartes University. This unit was created on January 1st, 2014 under the label INSERM/Paris Descartes and Paris Diderot Universities, by merging three teams working on Neuropharmacology. Including 40 permanent persons on its creation, this unit will involve 49 permanent members (about 15 equivalent full time without supporting personnel) for the next contract.

MANAGEMENT TEAM

The unit will be managed by the current director Mr Jean-Louis LAPLANCHE. The unit will be organized into three teams under the direction of Mr Frank BELLIVIER (head of team 1), Mr Bruno MÉGARBANE (head of team 2) and Mr Xavier DECLÈVES (head of team 3).

HCERES NOMENCLATURE

SVE5_3 Génétique médicale, Pharmacologie, Technologie médicales.

SCIENTIFIC DOMAIN

The unit's main objective is to optimize the monitoring of psychotropic treatments in neuropsychiatric patients. The unit develops basic and clinical research in neuropsychopharmacology using a translational research strategy to bridge the gap between clinic and basic research.

UNIT WORKFORCE

Unit workforce	Number 30/06/2017	Number 01/01/2019
Permanent staff		
Full professors and similar positions	9	12
Assistant professors and similar positions *Hospital practitioners*	16 *8*	15 7
Full time research directors (Directeurs de recherche) and similar positions	0	0
Full time research associates (Chargés de recherche) and similar positions	1	1
Other scientists ("Conservateurs, cadres scientifiques des EPIC, fondations, industries, etc.")	0	1
High school teachers	0	0
Supporting personnel (ITAs, BIATSSs and others, notably of EPICs)	14	20
TOTAL permanent staff	**40**	**49**
Non-permanent staff		
Non-permanent professors and associate professors, including emeritus	4	

Non-permanent full time scientists, including emeritus, post-docs	2	
Non-permanent supporting personnel	2	
PhD Students	13	
TOTAL non-permanent staff	**21**	
TOTAL unit	**61**	

GLOBAL ASSESSMENT OF THE UNIT

The unit is one of the few unit in France recognized for its expertise in neuropsychopharmacology in patients. The scientific production of the unit is very good to excellent. Most of the papers are published in highly-ranked specialized journals in the fields of Psychiatry, Emergency Medicine, Pharmacology and Pharmacy, Neurosciences and Toxicology. The unit is excellent in raising funds from national and international public research agencies as well as industrial companies. Several unit members are evaluators for national and international research funding agencies and participate in scientific committees, have been regularly requested by health authorities for specific questions or are consultants for pharmaceutical companies. Members are often invited to give lectures at national as well as international meetings and universities, suggesting that the unit has an excellent national/international visibility. The economic and social environment of the unit is very good to excellent. The contribution of the unit members to teaching and structuration of local academic life is remarkable. Despite the high quality of the scientific output, the unit did not access to very highly-ranked generalist journals. The unit has only one full-time researcher, which is rather few regarding the ambition of the project. The project seems overambitious for the current size of the unit. The unit has hardly attracted any foreign post-doctoral fellow, and not all researchers of the unit are involved in supervising PhD students or post-doctoral fellows.

The evaluation reports of Hceres
are available online : www.hceres.com

Evaluation of clusters of higher education and research institutions
Evaluation of higher education and research institutions
Evaluation of research
Evaluation of doctoral schools
Evaluation of programmes
International evaluation and accreditation

targeting quality
Hcéres